There has been substantial evolution in the treatment of metastatic renal cell carcinoma with
notable changes in the first-line setting. Currently, doublet combination therapy with either …

Background Immuno-oncology (IO) agents and tyrosine kinase inhibitors (TKIs) have
revolutionized the treatment paradigm for metastatic renal cell carcinoma (mRCC). Data on …

Simple Summary Kidney cancer occurs more commonly within the general population and
has historically been associated with morbidity and early death. The most common form of …

Objectives The treatment landscape for metastatic renal cell carcinoma changed a lot in the
last few years. This study aimed to assess the treatment sequences and outcomes for …

Background Immune checkpoint inhibitors can cause various immune-related adverse
events (irAEs). This study aimed to evaluate the association between the incidence of irAEs …

Abstract Background Immune-Oncology (IO) therapies have changed first-line (1L) treatment
paradigm for metastatic renal cell carcinoma (mRCC) in last few years with robust clinical …

Importance Immuno-oncology agents have changed the treatment paradigm for metastatic
renal cell carcinoma (mRCC). Such therapies improve survival but can impose considerable …

Simple Summary Recently, numerous treatments sharing similar mechanisms of action have
been approved for advanced renal cell carcinoma. These combinations prolong survival …

Purpose The purpose of our study was to determine whether data on the clinical
effectiveness of second-line therapy collected in a real-world setting provide additional …

Objectives The recent approval of first-line tyrosine kinase inhibitor plus immuno-oncology
agent combination therapy for the treatment of advanced renal cell carcinoma offers …